EGLN1 and prostate carcinoma: Here we identified a novel regulatory mechanism that hypoxia-responsive and HIF1α-regulated miR-182 acts as a positive regulator of HIF1α signaling by targeting negative regulators PHD2 and FIH1 in prostate cancer cells.